Medication info

Rocarb Tablets 30/5 mg

Prescription medicationTabletOral
Ingredient · strength
Fimasartan Potassium Trihydrate Granules›75mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
White, convex, octagonal film-coated tablet
Packaging
30 tablets (10 tablets/PTP packing x3), 100 tablets (10 tablets/PTP packing x10)
Approval status
Active

MFDS item code 201700490 · Approved 2017.01.25

Summary

Main use
Treatment of dyslipidemia and hypertension, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan/rosuvastatin. ○ Fimasartan 1. Adults The recommended dose is 30~60 milligrams once daily, administered regardless of food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect after approximately 8 weeks~12 weeks. 2. Older adults No initial dosage adjustment is required for older adults up to 70 years of age. (See section 9, Administration to Older Adults, under Precautions for Use.) 3. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), initiate treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Do not administer this medicine to patients with moderate to severe hepatic impairment (see section 2, Patients in Whom the Medicine Must Not Be Administered, and section 10, Administration to Patients with Hepatic Impairment, under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3, Administration with Caution, under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, adjust the dose to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is required. 3. Patients with renal failure No dosage adjustment is required in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
View approved original text

This medication is used for patients who require combined treatment with the two drugs, pimasartan and rosuvastatin. Pimasartan is primarily used for the treatment of essential hypertension. Rosuvastatin is primarily used to help improve hypercholesterolemia and dyslipidemia, a condition characterized by abnormally high levels of cholesterol and lipids in the blood. Additionally, it helps slow the progression of atherosclerosis and is used as an adjunct treatment for specific familial hypercholesterolemia patients. It also aids in reducing the risk of stroke, myocardial infarction, and arterial revascularization in adult patients with elevated high-sensitivity C-reactive protein levels and additional cardiovascular disease risk factors. This medication is used to improve cardiovascular health by managing both hypertension and hyperlipidemia simultaneously.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan/rosuvastatin. ○ Fimasartan 1. Adults The recommended dose is 30~60 milligrams once daily, administered regardless of food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect after approximately 8 weeks~12 weeks. 2. Older adults No initial dosage adjustment is required for older adults up to 70 years of age. (See section 9, Administration to Older Adults, under Precautions for Use.) 3. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), initiate treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Do not administer this medicine to patients with moderate to severe hepatic impairment (see section 2, Patients in Whom the Medicine Must Not Be Administered, and section 10, Administration to Patients with Hepatic Impairment, under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3, Administration with Caution, under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, adjust the dose to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is required. 3. Patients with renal failure No dosage adjustment is required in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to women with allergies to any of its components, women who are pregnant or may become pregnant, or nursing women. This medication should also not be administered to patients with severely impaired liver function, very poor kidney function, or certain muscle diseases. Caution is advised when using this medication in patients with low blood volume or sodium levels, weak kidney function, and certain heart diseases, and their conditions should be closely monitored during treatment. Muscle pain or weakness may occur during the course of treatment with this medication, so these symptoms should be reported to a doctor immediately. It may affect liver function; thus, it's essential to regularly monitor liver function tests before and during treatment. Interactions with other medications may occur, so you must inform healthcare professionals if you are taking other medications. Care should be taken when driving or operating machinery, as dizziness may occur. Store out of reach of children and avoid transferring to another container. Consult a healthcare professional immediately if any suspicious symptoms or adverse reactions occur during treatment with this medication.

Side effects

dyspepsia, nausea, fever, hepatitis, headache, dizziness, upper abdominal pain, esophagitis, gastroenteritis, nasopharyngitis, tonsillitis, upper respiratory tract infection, elevated ALT, elevated γ-GTP, elevated liver enzyme levels, increased white blood cell count, urinary disorder, frequent urination, cough, hyperkalemia, arthralgia, insomnia, pruritus, syncope, sedation, migraine, vomiting, asthenia, foreign body sensation, decreased platelet count, increased serum creatine phosphokinase, muscle contractions, muscular rigidity, localized urticaria, facial flushing, flushing, erectile dysfunction, constipation, abdominal pain, vascular edema, diabetes, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, bruising, thrombocytopenia, increased serum creatinine, acute kidney failure, chest pain, back pain, limb pain, facial edema, fatigue, fever, neck/shoulder pain, fracture, joint disease, muscle weakness, pharyngitis, upper respiratory tract infection, sputum, rhinitis, nosebleed, bronchitis, sensory abnormalities, numbness, tremors, hypertonia, anxiety, memory impairment, loss of appetite, gastroesophageal reflux, gastritis, diarrhea, functional gastrointestinal disorder, urinary incontinence, kidney stones, chronic kidney failure exacerbation, abscess, bacterial infection, genital herpes, cold sores, shingles, myeloproliferative disorder, anemia exacerbation, iron deficiency anemia, tinnitus, hearing impairment, hearing loss, pelvic inflammatory disease, vaginitis, benign prostatic hyperplasia, scrotal pain, blood pressure fluctuations, fatty liver, localized inflammation, soft tissue infections, lymphadenopathy, purpura, allergy, chills, nasal polyps, edema, peripheral edema, increased blood pressure, purpura

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent air and moisture from entering. Keep the storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

White, convex, octagonal film-coated tablet

Package unit

30 tablets (10 tablets/PTP packing x3), 100 tablets (10 tablets/PTP packing x10)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.